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Investigations on Cancer Cell  
Biological Effects of CDK8 Inhibitor Q-12  
 
 
Abstract 
 
 
by Zhixin Lu 
 
University of the Pacific 
2018 
 
 
Over the past two decades, protein kinases have been intensively investigated as 
targets to treat neoplastic diseases.  Many protein kinase inhibitors not only have 
therapeutic potential but are becoming invaluable reagents for the study of cell signaling. 
We aspired to use our Cyclin-Dependent Kinase 8 inhibitor, Q-12, as a probe for 
biomarker discovery for CDK8 inhibitor sensitive tumor types.  Q-12 shows potent 
inhibition of cell viability and induction of apoptosis process in some triple-negative 
breast cancer and colorectal cancer cell lines in vitro.  Western blot results indicate that 
the reduction of STAT1 phosphorylation could be a robust indicator of CDK8 target 
engagement in all three cancer cell lines used upon Q-12 treatment.  Q-12 treatment of 
triple-negative breast cancer cell line (MDA-MB-468) decreases STAT1 phosphorylation 
but increases STAT3 phosphorylation.  Q-12 activity in MDA-MB-468 cell is dependent
 5 
on the activation of STAT3 phosphorylation.  All results suggest that there may be a 
critical STAT1 to STAT3 ratio that may serve as a biomarker for CDK8 inhibitor 
sensitivity.  In this precision medicine era, the discovery of biomarker is urgently needed 
to minimize the risks of severe side-effects by traditional chemotherapy and improve 
diagnosis and monitor therapy response across a wide spectrum of disease, especially 
heterogenous type of disease, like cancer.  
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Background 
 
Cyclin Dependent Kinase  
Cyclin-dependent kinases (CDKs) are a protein kinases family whose activity 
depends on a regulatory subunit – a cyclin.  CDKs are present in a variety of key 
regulatory pathways in all known eukaryotic cells and phosphorylate their substrates on 
serines and threonines (1).  CDKs play important roles in the control of cell division and 
modulate transcription in response to several extra- and intracellular cues (2).  Over the 
course of evolution, both CDK and cyclin gene families have independently undergone a 
significant number of functional specializations (3). 
 Many of the interactions between specific mammalian CDKs and cyclins have 
been reported in vitro.  CDKs are considered a potential target for anti-cancer treatment.   
At present, some CDK inhibitors such as seliciclib, which is undergoing clinical trials, 
have been found to produce apoptosis in treated cancerous cells of non-small cell lung 
cancer (NSCLC) and other cancers (4).  Palbociclib and ribociclib are both orally active, 
highly selective reversible inhibitors of CDK4 and CDK6 that are approved by the U.S. 
Food and Drug Administration (FDA) for hormone receptor-positive metastatic breast 
cancer in combination with specific endocrine therapies (5).  
In an evolutionary analysis of CDK and cyclin proteins in metazoans and their 
unicellular relatives, Cao., el (3) found that the CDK family could be divided into eight 
subfamilies.  Seven subfamilies (CDK1/2/3, CDK5, CDK7, CDK 20, CDK8/19, CDK9  
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and CDK10/11) are conserved in metazoans and fungi, with CDK4/6 subfamily found 
only in eumetazoans. 
It is very likely that new targets within the CDK family will be explored in the 
near future for therapy of cancer or other diseases. 
As for main function of cyclin-dependent kinase 8 in cancer, it responds to several 
intracellular signaling pathways, and it has been linked to many different processes, 
including cellular growth, proliferation and differentiation (7).  
One of the most important activities of CDK8 is associating kinase complexes 
such as P-TEFb or TFIIH to phosphorylate important regulatory sites within the STAT 
transcription factor family.  STAT transcription factors play an important role in immune 
response and cancer development (4).  CDK8 was found to phosphorylate STAT1 at the 
S727 site and was identified as a key regulator of STAT1 (6).  
CDK8 has multiple targets and phosphorylates several transcription factors, 
affecting their stability and activity.  The role of CDK8 in colorectal cancer is 
documented by far the best in regulation of β-catenin-dependent gene expression. 
Evidence suggests that CDK8 functions as a potent oncogene in colon cancer through 
WNT/β-catenin signaling pathway coactivating within the p53 transcriptional program 
(8,9).  
An interesting study (10) by the Dyson lab emphasized the importance of CDK8 
for β-catenin activity in a process involving the transcriptional regulator E2F1.  In human 
cells, E2F1 strongly repressed β-catenin-dependent transcription and induced degradation 
of β-catenin.  CDK8 was found to bind and phosphorylate E2F1 in vitro, suggesting that 
CDK8 inhibits the repressive activity of E2F1 towards β-catenin.  It appears that CDK8 
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acts directly and indirectly to both enhance β-catenin transcriptional activity and to 
release it from the inhibitory effect of E2F1.  Active E2F1 was found to repress the 
activity of β-catenin transcription and promote cell apoptosis and this activity was found 
to be antagonized by a direct CDK8 phosphorylation at Ser375 (11). 
There is a CDK8 study (12) that found transfection of MicroRNA-26b (miR-26b) 
mimics into breast cancer cell lines (MDA-MB-231 and MCF-7 cells) significantly 
suppressed cellular proliferation by directly interacting with the CDK8 3’UTR and 
downregulated CDK8 mRNA and protein levels in breast cancer cells. 
The aforementioned studies suggest that CDK8 is a promising novel target in 
oncology and presents a potentially attractive target for small molecule intervention to 
precisely act on context-related gene expression (13).  In 2013 to 2014, many CDK8-
specific inhibitors are found in patent applications.  With a deeper understanding of very 
specific CDK8 activity in cancer, we are hoping to reach a robust responder hypothesis 
and personalized clinical approach (13,14).   
  Previous work done by Dr. Russu et al (15) has identified a novel kinase 
inhibitor known as Q-12, a novel compound that contains the direct attachment of the 
quinazoline fragment to the piperazinylpyrimideine scaffold (Figure 1), which has shown 
moderate selectivity toward CDK8 and c-KIT, another protein kinase involved in cellular 
signal transduction pathways.  
 
 
 
 
 
Figure 1.  Chemical structure of Q-12 
N
N
N N
N
N
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To test the potential of Q-12 to bind with the human kinome that was designed to 
target, a kinase binding assay was used to exam the ability of 10 µM of Q-12 to interfere 
with the binding of a given kinase with an immobilized, ATP directed agent. A single 
dose of 10 µM was chosen to allow for the detection of the kinases able to bind Q-12, 
followed by dose-response binding experiments.  The competition with ATP for the 
binding and inhibition of CDK8 kinase and KIT kinases, is displayed as the dissociation 
binding constant (Kd) in Table 1. 
 
  
 
Table 1.  Kinase binding and inhibition data for Q-12. 
 
Kinase Kd (µM) 
CDK8 0.46 
KIT 2.5 
KIT(D816H) mutant 1.3 
KIT(D816V) mutant 0.11 
 
 
 
Q-12 exhibited obvious tendency to bind strongly in the ATP binding site of wild-
type and/or mutant members of the CDK8 and KIT subfamilies, which indicated that Q-
12 is an ATP competitive inhibitor of cyclin dependent kinase 8 (CDK 8).  Of the wild 
type kinases, Q-12 had the highest affinity for CDK8. 
An anti-proliferative activity test was performed through screening Q-12 (Figure 
1) against the NCI-60 tumor cell line panel, which revealed that Q-12 was effective at 
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inhibiting select cell lines (Table 2).  Cell lines that contained APC mutations showed 
apparent resistance to Q-12.  
 
 
 
Table 2. GI50 (µM) values for Q-12 against selected cell line with corresponding AKT 
pathway activation and PTEN/APC mutation status. 
 
Cell Line Q-12 GI50 APC Mutant 
MDA-MB-468 0.05 No 
RPMI-8226 0.31 No 
NCI-H23 0.44 No 
SF-295 0.31 No 
HCT-116 0.27 No 
BT-549 1.3 No 
K-562 0.47 No 
NCI/ADR-Res 0.63 No 
T-47D 0.71 No 
KM12 12.6 Yes 
SW-620 12.8 Yes 
HCC-2998 15.9 Yes 
HT29 15.5 Yes 
COLO-205 30.4 Yes 
OVCAR-3 11.2 Yes 
HCT-15 19.4 Yes 
SK-OV-3 25.5 Yes 
 
 
 
Among all cell lines in NCI-60 cell panel, triple-negative breast cancer cell line, 
MDA-MB-468 shows the most sensitivity to Q-12 (GI50=0.06 µM).  The colon cancer 
cell line, HCT-116, the only colon cancer cell line without APC mutation shows high 
sensitive to Q-12 (GI50= 0.27 µM) as well.  
Table 3 indicates that the activity of Q-12 is likely due to CDK8 inhibition, 
instead of KIT inhibition.  As shown Imatinib significantly inhibits the tyrosine kinase 
activity of KIT, compare to Q-12.  Imatinib did not have potent GI50 value profile in 
HCT-116 cell line and other cell lines in NCI-60 cell panel, while Q-12 did. 
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Table 3. Kinase binding ability and GI50 (µM) values of c-KIT inhibitors (Q-12 and 
Imatinib) against HCT-116 cell line. 
 
 
 
 
 
Breast Cancer  
 
An estimated 1.67 million new breast cancer cases were diagnosed in 2012 (25% 
of all cancers).  Breast cancer is the second most common cancer in the world and ranks 
as the fifth cause of death from cancer overall.  It is the most frequent cancer in women 
both in more and less developed regions with slightly more cases in less developed 
regions (16).  
Breast cancer is highly heterogenous and can be histologically differentiated into 
21 subtypes on the basis of cell morphology and growth.  Based on different gene 
expression profiling, breast cancer can be molecularly categorized in at least four 
subgroups with different prognosis and sensitivity to treatment (17).  
The main molecular classification of breast cancer has been distinguished by gene 
expression profiling into intrinsic subtypes by Peru et at (18).  In clinical practice, 
routinely used subtypes of breast cancer are categorized based on the profiles of three 
markers, including hormonal receptors: estrogen, progesterone receptors and growth 
factor receptor: human epidermal growth factor receptor 2 (HER2).  Based on receptor 
levels, breast cancer can be divided into luminal A, luminal B, HER2 enriched and triple 
negative (19).  Luminal A type of breast cancers express estrogen receptor (ER) and/or 
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progesterone receptor (PR) but lack HER2 amplification.  They are relatively less 
aggressive and slow growing.  Compare to luminal A type, luminal B type is more 
aggressive (20) and also overexpress HER2.  As the name indicates, HER2 enriched 
subtype of breast cancers have amplified HER2 expression but lack the expression of 
both hormonal receptors and they have poor prognosis compare to luminal subtypes (21).  
Triple negative breast cancers (TNBC) are the most aggressive and recurring type 
of breast cancers with the poorest prognosis of all subtypes.  The 5-year survival rate of 
TNBC patients is 77%, which is significantly lower compared to 93% in non-TNBC 
patients (22).  Besides lacking estrogen receptor (ER), progesterone receptor (PR) and 
HER2 amplification, TNBC also often overexpress the EGFR (23).  Besides 
overexpression of EGFR, lack of the identification of common oncogenic driver makes 
TNBC highly challenging for targeted therapy.  
Based on TNBC molecular profiles, many studies have worked to classify TNBC 
into different subtypes.  Lehmann et al. classified TNBC into six subgroups based on 
unique gene expression profiling and ontologies, including two basal-like (BL1 and 
BL2), a mesenchymal (M), a mesenchymal stem-like (MSL), an immunomodulatory 
(IM) subtype, and a luminal androgen receptor (LAR) subtype (24).  
Although extensive TNBC molecular profiling has been established, there is no 
targeted therapy for TNBC so far, which limit the treatment options to traditional 
chemotherapy, radiation and surgery.  Because of the different genetic and epigenetic 
makeups and molecular characteristics of TNBC, there is a need for establishing targeted 
therapy directed towards specific tumor pathology or signaling pathways to minimize 
severe side-effects of unnecessary and ineffective treatments.  Drug sensitivity based 
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phenotypic profiling of TNBC and biomarker-based patient stratification in clinical trials 
will also play an important role in the field of modern precision medicine. 
Colorectal Cancer  
 
Cancer is a disease characterized by the unchecked division and survival of 
abnormal cells.  When this type of abnormal growth occurs in the colon or rectum, it is 
called colorectal cancer (CRC) (25).  In 2017, there were estimated 95,520 new cases of 
colon cancer and 39,910 cases of rectal cancer diagnosed in the US.  Approximately 
4.6% of men (1 in 22) and 4.2% of women (1 in 24) will be diagnosed with CRC in their 
lifetime (26). 
Adenomatous polyposis coli (APC) and its regulation of β-catenin plays a key 
role in colon cancer initiation and development.  APC is a protein that in humans is 
encoded by the APC gene, which is classified as a tumor suppressor gene.  Mutation of 
APC has been found in more than 80% of all colorectal carcinomas and adenomas plays 
an important role in the progression and early development of colorectal cancer (27,28).  
In the absence of functional APC, Wnt/β-catenin signaling pathway is constitutively 
activated.  Consequently, β-catenin is deregulated and promotes aberrant transcription of 
its target genes (29).  Besides the ability of regulating the total cellular level of β-catenin, 
APC is also involved in protein transport and cell adhesion by modulating E-cadherin 
localization (30).  To better understand the molecular mechanisms of APC function in β-
catenin degradation, a study (31) has been done to examine the effects of APC mutations 
on β-catenin phosphorylation, ubiquitination and degradation in different colon cancer 
cell lines.  Results suggested that APC regulates β-catenin phosphorylation and 
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ubiquitination by distinct domains under different and complicated molecular 
mechanisms.  
Following study (32) on the post-transcriptional modifiers of β-catenin that 
participate in colon cancer, CDK8 was found amplified in most types of colon cancers. 
All observations indicated that CDK8 with a strong suppressor of E2F1 can regulate β-
catenin activity, which brought up a potential treatment trend for colon cancer. Targeting 
the CDK8 kinase activity appears to have clinical value and benefit in not only colorectal 
cancer, but also other β-catenin-driven malignancies (33).  
The treatment of colorectal cancer in clinic has advanced rapidly over the past 
several decades, including improvements in surgical techniques and chemotherapy. 
However, it has also become increasingly clear that treatment outcomes vary widely 
based on tumor-specific molecular features (34).  At the same time, there are many 
temporary and long-term side-effects coming along during traditional cancer treatment.  
Targeted therapy is a new area of colorectal cancer drug development resulting 
from increased understanding of the molecular changes involved in cancer occurrence. 
These drugs target specific molecules involved in tumor growth and progression and have 
different, often less severe side effects than conventional chemotherapy drugs (25,34).   
Altogether, targeting the CDK8 kinase activity appears to have clinical value and benefit 
in not only colorectal cancer, but also other β-catenin-driven malignancies (33).  
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Aim of study 
 
The main aim of the study is to understand cancer cell biological effects of CDK8 
inhibitor Q-12 and the mechanisms of anti-proliferative effect of Q-12 in order to further 
identify potential biomarkers for human cancer sensitivity to CDK8 inhibitors. 
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Materials and methods 
 
Cell lines, chemicals and antibodies: MDA-MB-468 human breast cells, COLO-
205 human colon cells and HCT-116 human colon cells were obtained from ATCC, 
USA. MDA-MB-468 and COLO-205 were grown in Gibco® RPMI-1640 medium 
(Thermo Fisher Science, San Jose, CA, USA), HCT-116 was grown in McCoy’s 5a 
medium (Hyclone, Logan, Utah).  All media were supplemented with 10% FBS (Gemini 
Biological Products, Calabasas, CA), 1% Antibiotic-Antimycotic mixture of Penicillin-G, 
Streptomycin sulfate and Amphotericin B (Thermo Fisher Science, San Jose, CA, USA).  
The cells were maintained in a humidified incubator at 37 °C with 5% CO2.  Q-12 stock 
solution: 3.3 mg Q-12 into 1 mL DMSO to make 10 mM Q-12 stock solution. Antibodies 
to STAT1, p-STAT1 (Ser727), p-STAT3 (Tyr705), β-catenin, IAP family (Livin, 
Survivin, XIAP, C-IAP1, C-IAP2), Bcl-2 family (Bcl-xL, Bcl-2, p-Bcl-2 (Ser70), p-Bcl-2 
(Thr56), Mcl-1) and GAPDH were obtained from Cell Signaling Technology Inc 
(Beverly, MA, USA). 
Measurement of cellular viability: Cells were grown in T25 flask format at a 
density of 1×106 cells/ flask.  After 24 h of culture, cells were treated with DMSO 
(vehicle) or 10 µM Q-12 for the indicated time period.  Cell lines were sub cultured by 
enzymatic digestion with 0.25% trypsin/EDTA solution when they reached 
approximately 70-80 % confluency.  Floating cells and adherent cells were collected after 
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the various treatments.  Cells were washed twice with 1× PBS and re-suspended in fresh 
media for cell viability assay.  Cell viability was measured with the Muse Cell Analyzer 
(Millipore, Hayward, CA, USA) using the Muse Count and Viability Kit (Millipore, 
Hayward, CA, USA) which differentially stains viable and dead cells based on their 
permeability to two DNA binding dyes.  Data were presented as proportional viability 
(%). 
Quantification of apoptosis by Annexin V labeling: For apoptosis profiling assay, 
cells were treated with DMSO (vehicle) or 10 µM Q-12 for 24 h.  Detached and adherent 
cells were collected and incubated with Annexin V and 7-AAD, a dead cell marker, for 
20 min at room temperature in dark.  The events for live, dead early and late apoptotic 
cells were counted with the Muse Cell Analyzer (Millipore, Hayward, CA, USA). 
Western blotting analysis: After treatment of MDA-MB-468, COLO-205 and 
HCT 116 cells with 10 µM Q-12 for 24 h, cells were collected and washed twice with 
ice-cold 1×HBSS, then lysed in Cell Lysis Buffer (Cell Signaling Technology Inc, 
Beverly, MA, USA), supplement with protease inhibitor (Sigma, USA) on ice for 10 min 
before scrapping.  Cell lysates were then centrifuged for 10 min at 13,000 rpm at 4 °C.  
Protein concentration of lysates was determined by BCA protein assay kit (Thermo 
Scientific, San Jose, CA, USA) and the lysates were adjusted with lysis buffer. Proteins 
were separated using SDS-PAGE and subsequently transferred to nitrocellulose 
membranes (Thermo Scientific, San Jose, CA, USA).  The blots were blocked with 5 % 
BSA (20 mM Tris HCL, pH 7.5, 137 mM NaCl and 0.05 % Tween-20) at room 
temperature for 1 h. Incubation with specific primary antibodies was performed in 
blocking buffer overnight at 4°C.  After washing with TBST, the blots were incubated 
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with secondary antibody (IRDye 800 CW Donkey anti-rabbit 926-32213) for 1 h.  To 
ensure equal protein loading, GAPDH was used as an internal control.  The protein bands 
were detected and quantified with the Odyssey infrared imaging system (LI-COR 
biosciences, Lincoln, NE, USA). 
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Results 
 
Chapter 1. CDK8 inhibitor Q-12 effects on cancer cell line viabilities and apoptosis 
induction 
1.1 Q-12 effects on cancer cell line viabilities 
From GI50 value for Q-12 against selected cancer cell lines (Table 2), Q-12 shows 
anti-proliferative function.  To examine the anticancer activity of Q-12 on breast cancer 
and colorectal cancer cells in vitro, we first examined the effect of Q-12 on cell 
proliferation of MDA-MB-468, COLO-205 and HCT-116 cells.  
 
 
 
  
Figure 2. Cell viability of Q-12 treated cell lines vs control.  Data represent the mean 
±SD of at least three independent experiments.  Student's t test was performed to 
determine the significance (p=<0.001).  
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Exponentially growing MDA-MB-468, COLO-205 and HCT-116 were treated 
with vehicle (DMSO) and 10 µM Q-12 for 72 h.  Our results show that the exposure of 
the MDA-MB-468, COLO-205 and HCT-116 cells to Q-12 decreased cellular viability.  
Cells were assayed with the Muse Cell Analyzer as described by the manufacturer.  
1.2 Q-12 effects on cancer cell line apoptosis induction 
Next, we investigated whether the observed growth inhibition upon Q-12 
treatment was associated with induction of apoptosis.  Annexin V binding was carried out 
using Annexin V & Dead Cell kit (Millipore).  Cells were treated with DMSO or 10 µM 
Q-12 for 24 h.  Detached and adherent cells were collected and stained with Annexin V 
and 7-AAD.  Then the events for early and late apoptotic cells were counted with the 
Muse Cell Analyzer as described in Materials and Methods. 
 
 
 
 
Figure 3. Q-12 induced apoptosis in cancer cell lines, control vs treated. Data represent 
the mean ±SD of at least three independent experiments.  Student's t test was performed 
to determine the significance (p=<0.001).  
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         Following 24 hours of treatment, Annexin V staining was detected in cells treated 
with 10 µM of Q-12 (Figure 2), indicating that MDA-MB-468 and COLO-205 cells were 
undergoing apoptosis upon Q-12 treatment. 
1.3 Inhibitor of apoptosis and pro-survival Bcl-2 family protein expression in 
cancer cell lines 
To further understand the role of Q-12 in apoptosis in MDA-MB-468 and COLO-
205 cell lines, we used Western blotting to detect inhibitors of apoptosis proteins (IAP) 
family and pro-survival Bcl-2 family in non-treated cancer cells (Figure 4).  
 
 
 
 
 
Figure 4. Western blotting analysis of IAP family (c-IAP1, c-IAP2, Survivin, XIAP, 
Livin) and Bcl-2 Family (p-Bcl-2(Ser70), p-Bcl-2(Thr56), Bcl-2, Bcl-xL, Mcl-1) in 
MDA-MB-468 and COLO-205 cell lines.  Blots in figure are represented of three 
independent experiments performed in triplicate.  
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The expression of Survivin, XIAP, Bcl-2 and Mcl-1 are relatively high in MDA-
MB-468 cell line and the expression of XIAP, Bcl-2, Mcl-1 and Livin are relatively high 
in COLO-205 cell line (Figure 6,7).  These are the proteins we chose to investigate 
further with Q-12 treatment.  
1.4 Q-12 effects on cancer cell line inhibitor of apoptosis and pro-survival 
Bcl-2 protein expression  
We focused on Survivin, XIAP, Bcl-2 and Mcl-1 in MDA-MB-468 cell line and 
XIAP, Bcl-2, Mcl-1 and Livin in COLO-205 cell line upon 10 µM Q-12 treatment to see 
how Q-12 affected those protein expressions.  
 
 
 
 
 
 
 
Figure 5. A. Bcl-xL, Mcl-1, Survivin and XIAP expression in MDA-MB-468 cell line 
upon 24 h 10 µM Q-12 treatment. B. Bcl-xL, Mcl-1, Livin and XIAP expression in 
COLO-205 cell line upon 24 h 10 µM Q-12 treatment.  Blots in figure are represented of 
three independent experiments performed in triplicate.  
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Among all those high expressed IAP and pro-survival Bcl-2 family members, we 
found out that the expression of Mcl-1 was downregulated upon Q-12 treatment in both 
MDA-MB-468 (30% decrease) and COLO-205 (70% decrease) cell lines, which 
indicates Q-12 can modulate the expression Mcl-1 in those cell lines. 
1.5 Q12 effects on cancer cell line pro-apoptosis Bcl-2 protein expression 
We further studied the expression of common pro-apoptosis Bcl-2 proteins (BAD, 
BOK, BIM, BIK, NOXA, BID, PUMA, BAX and BAK) upon 10 µM Q-12 treatment. 
 
 
 
 
Figure 6. Pro-apoptosis Bcl-2 Family expression (BAD, BOK, BIM, BIK, NOXA, BID, 
PUMA, BAX and BAK) in MDA-MB-468 cell line upon 24 h 10 µM Q-12 treatment.  
Blots in figure are represented of three independent experiments performed in triplicate.  
 
 
 
Among all pro-apoptosis Bcl-2 family, PUMA and BAK expression were up-
regulated upon 24 h 10 µM Q-12 treatment.  There are three-fold differences between 
PUMA expression between control and Q-12 treated group and 1.75-fold differences 
between BAK expression between control and Q-12 treated group.  
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            1.6 Discussion  
Programmed cell death (PCD) plays an important role in determining cancer cell 
fate.  Apoptosis, autophagy and programmed necrosis are the three main forms of PCD, 
which could be distinguished by their morphological differences (35).  
Apoptosis was first described by Kerr et al. (36) with characteristics of cell 
shrinkage, nuclear condensation and fragmentation, membrane blebbing or loss of 
adhesion.  Studies indicated that autophagic cells may commit suicide by undergoing cell 
death to cope with excessive stress (37).  The third type of PCD is necrosis.  In this type 
of programmed cell death, the cell could be found swelling, organelle dysfunction and 
lysis.  The cross-talk among apoptosis, autophagy and programmed necrosis was found 
under certain circumstances in cancer cells.  Among those three types, apoptosis has now 
been widely accepted as a dominant tumor-suppression mechanism. 
Bcl-2 family of proteins can program cancer cells commit to apoptosis by 
interaction between its three subfamilies: anti-apoptosis Bcl-2 family, pro-apoptosis Bcl-
2 family and Bcl-2 homology regions 3 (BH3) (38).  The initial cell death signal is 
guided by BH3 - only protein group, including BAD, BID, BIM, PUMA and NOXA, 
which have in common only at BH3 interaction domain.  When BH3-only proteins are 
induced or activated, they interact and pair with core Bcl-2 family proteins, such as Mcl-
1, BAX, BAK, to promote apoptosis.  BH3-only proteins can be activated post-
translationally and their expression can also be induced by transcription factors (39).  
According to the result of apoptosis protein expression of MDA-MB-468 cell line 
upon Q-12 treatment, expression of pro-apoptosis proteins, PUMA and BAK were up-
regulated.  Mcl-1, one of pro-survival Bcl-2 protein members, was down-regulated.  At 
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the same time, PUMA and BAK, as BH3 domain only protein, can be recognized and 
paired with Mcl-1, which will shift the equilibrium to apoptosis more dramatically (40). 
That may explain the apoptosis process happened in MDA-MB-468 cell line upon Q-12 
treatment.  Since Q-12 is affecting gene transcription of apoptosis proteins, we further 
investigated the transcription factors that may involve in Q-12 modulation.  
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Chapter 2. CDK8 inhibitor Q-12 effects on transcription factor proteins 
 
2.1 Q-12 effects on transcription factor proteins: β-catenin and STAT1 
In the cell nucleus, β-catenin interacts with the TCF/LEF transcription factors to 
drive the transcription of WNT target genes, which is essential for β-catenin oncogenic 
activity (41).  CDK8, as a colon cancer oncogene, has been found amplified in certain 
subset of colon cancers and playing an important role in the regulation of nucleus β-
catenin transcription activity.  STAT1, is a direct substrate of CDK8.  The 
phosphorylation of STAT1 at Ser 727 site has been demonstrated as a pharmacodynamic 
biomarker of CDK8 activity (42).  Based on that, we turned to investigate the expression 
of both β-catenin and p-STAT1 (Ser 727) upon CDK8 inhibitor Q-12 treatment. 
 
 
 
 
Figure 7. β-catenin and p-STAT1 Expression in MDA-MB-468 and colon cancer lines: 
COLO-205 and HCT-116 upon 24 h10 µM Q-12 treatment. Blots in figure are 
represented of three independent experiments performed in triplicate.  
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In both colorectal cancer cell lines, COLO-205 and HCT-116, there is an obvious 
decrease of β-catenin content.  If β-catenin is important for the survival of colon cancer 
cell lines like the other study reported (41), it makes sense that the decrease of colon 
cancer cell viability is related to the decrease of β-catenin expression.  While, in triple-
negative breast cancer cell line, MDA-MB-468, there isn’t much change of β-catenin 
upon Q-12 treatment.  As for STAT1 expression, all three cancer cell lines have a 
decrease of STAT1 phosphorylation at Ser 727 site, which is assumably going to affect 
gene expression.  
Here we have both β-catenin and p-STAT1 expression being modulated by Q-12 
in colon cancer cell lines, HCT-116 and COLO-205, but only p-STAT1 was modulated in 
the breast cancer cell line.  
One study (43) defined STAT1 as a novel transcription target of the nucleus 
EGFR-STAT3 transcription complex in breast cancer cell lines.  They characterized 
STAT3 can enhance STAT1 gene expression and STAT transcription factors are key 
regulators of cell proliferation, apoptosis and tumor progression.  They also considered 
the compensatory mechanism between STAT transcription factors, especially STAT1 and 
STAT3.  Besides the crosstalk between STAT1 and STAT3, CDK8 was found to have 
the role of phosphorylating the transactivation domain (TAD) of STAT1, STAT3, and 
STAT5, which regulates the transcriptional activity of the STATs (44).  The central role 
of CDK8 in STAT-dependent cytokine responses make it a promising therapeutic target 
within the STAT pathway.  This evidence leads us to further study STAT3 expression in 
those cancer cell lines upon Q-12 treatment.  
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2.2 Q-12 effects on transcription factor protein: STAT3 
Signal transducer and activator of transcription (STAT) family proteins are key 
regulators of cell proliferation, apoptosis and tumor progression.  Among them, STAT3 
plays a dual role in tumor inflammation and immunity by promoting pro-oncogenic 
inflammatory pathways, such as interleukin-6 (IL-6) pathway, and by involving in 
STAT-1 anti-tumor immune responses (45).  STAT3 can also exert either oncogenic or 
anti-cancer effects through transcriptional regulation of target genes in cancer cells 
directly or being modulating tumor angiogenesis and anti-tumor immune response 
indirectly (46).  The alternations of the balanced expression and/ or activation of STAT1 
and STAT3 appears important for further developing promising compound that could 
regulate the STAT1:STAT3 equilibrium in the design of cancer therapeutic interventions, 
which lead us further studied the STAT3 expression upon Q-12 treatment in COLO-205 
and MDA-MB-468 cell lines.  
 
 
 
 
Figure 8. STAT3 and p-STAT3 (Tyr705) expression in MDA-MB-468 and COLO-205 
cell lines upon 24 h 10 µM Q-12 treatment.  Blots in figure are represented of three 
independent experiments performed in triplicate.  
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From the observation of western blotting result, there is no change as for total 
STAT3 expression upon Q-12 treatment in both COLO-205 and MDA-MB-468 cell 
lines.  For p-STAT3 (Tyr 705), the expression is low and there wasn’t change between 
the control and treatment groups in COLO-205; but, there is a definitely up-regulation in 
MDA-MB-468 upon Q-12 treatment. 
A study (47) specifically focused on cell lines with EGFR overexpression, 
including MDA-MB-468 cell line, has showed that activation of STAT3 phosphorylation 
can reduce MDA-MB-468 cell viability and induce apoptosis through either EGF 
(through EGFR) or OSM (IL6 family member).  They also show that siRNA of STAT3 
can slightly protect the cells.  Their findings indicate that STAT3 serves as a positive 
mediator of EGF-induced apoptosis in MDA-MB-468 cells.  Another study (48) from the 
Lo group reported for the first time that STAT1 gene expression could be enhanced by 
STAT3 in the presence of ErbB family of receptor tyrosine kinases, including EGFR, 
EGFRvⅢ and HER2.  The positive association between expression levels of STAT1 and 
STAT3, involving transcriptional activation of the STAT1 gene by STAT3.  In summary, 
based on literature and our results, it is likely that the STAT1:STAT3 balance is closely 
controlled by the inflammatory signals and growth factors.  The balance will further 
determine the cell fate.  
Since we’ve observed apoptosis effect in MDA-MB-468 cells, we want to 
investigate whether STAT3 activation was important for the previous apoptosis effect. 
Our hypothesis is by inhibiting phosphorylated STAT3 activity in MDA-MB-468 cells, 
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the cell viability decrease caused by Q-12 will be attenuated, which was confirmed by 
following experiment.  
2.3 STAT3 inhibitor experiment - Cell Viability 
Cryptotanshinone (CPT) is a selective STAT3 inhibitor with IC50 of 4.6 µM in a 
cell-free assay, strongly inhibits phosphorylation of STAT3 Tyr705, with a small effect 
on STAT3 Ser727, but none against STAT1 nor STAT5.  We examined the cell viability 
of MDA-MB-468 cells upon 72 h three different treatment conditions.  
 
 
 
 
Figure 9. Effect of STAT3 inhibitor on Q-12 treated and untreated MDA-MB-468 cells. 
Data represent the mean ±SD of three independent experiments.   
 
 
 
Compared to control, MDA-MB-468 cell viability with 10 µM CPT alone had an 
nonsignificant decrease much, which indicating the CPT isn’t toxic to MDA-MB-468 cell 
line.  The second group with co-treatment of 10 µM CPT and 10 µM Q-12 had more cell 
death than CPT alone group, which indicates that Q-12 can still induce the cell death 
process in the presence of CPT, but not as much as the third group, which was Q-12 
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alone.  These results show that CPT can rescue MDA-MB-468 cells from treatment with 
Q-12, suggesting that STAT3 phosphorylation plays an important part in the Q-12-
mediated killing the MDA-MB-468 cells.  In all, Q-12 activity in MDA-MB-468 cell line 
is dependent on the activation of STAT3 phosphorylation.  
To further understanding the role of STAT3 in apoptosis induction upon Q-12 
treatment in MDA-MB-468 cell, we further studied the expression of Bcl-2 family 
member: PUMA, BAK and Mcl-1, which have been previously shown their involvement 
in Q-12 treatment.  
2.4 PUMA, BAK, Mcl-1 expression upon co-treatment with Q-12 and STAT3 
inhibitor 
For the experiment, we used control groups, Q-12 treatment groups and Q-12 and 
CPT co-treatment groups.  
 
 
 
 
Figure 10. Effect of co-treatment with Q-12 and STAT3 inhibitor on expression of Mcl-1, 
BAK, PUMA in MDA-MB-468 cells. Blots in figure are represented of three independent 
experiments performed in triplicate.  
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Compare to control group, the expression of p-STAT3 (Ser727) had 2-fold 
increase upon Q-12 treatment.  The expression of p-STAT3 (Ser727) in CPT and Q-12 
co-treatment group decreased 2-fold compared to Q-12 treatment group, which indicated 
the CPT was able to inhibit p-STAT3 activation at Ser727 site, which was caused by Q-
12 in MDA-MB-468 cells.  Mcl-1 expression was decreased due to Q-12 treatment, but 
co-treatment with CPT and Q-12 restored normal expression level of Mcl-1.  The pro-
apoptosis protein, PUMA, was upregulated by Q-12, while its expression was attenuated 
by CPT and Q-12 co-treatment, which similarly to Mcl-1 links its expression to STAT3 
phosphorylation.  Another pro-apoptosis protein BAK, was not modulated by CPT co-
treatment.  STAT3 inhibitor, CPT, regulated apoptosis proteins: Mcl-1 and PUMA, 
which were modulated by Q-12.  These results suggest that Q-12 activity in MDA-MB-
468 cell line is dependent on the activation of STAT3 phosphorylation. 
2.5 Discussion  
From the above results of the expression of Mcl-1, BAK and PUMA in MDA-
MB-468 cells upon co-treatment with Q-12 and STAT3 inhibitor, we concluded that Mcl-
1 and PUMA were modulated by Q-12 and p-STAT3 was synergistically involved in 
apoptosis process, which was induced by Q-12 in MDA-MB-468 cells.  BAK was not 
involved in STAT3 phosphorylation upon CPT treatment.  The decrease of BAK 
expression may be due to the indirect reaction of the cells upon Q-12 treatment, not 
linking to STAT3 signaling.   
STAT3 activation can also occur through interleuin-6 (IL-6), epidermal growth 
factor, vascular endothelial growth factor, etc. (43) IL-6 was shown to serve as an 
activator of STAT3 in breast cancer.  A positive correlation between IL-6 and p-STAT3 
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expression levels was found in primary breast cancers and IL-6 family of cytokines (49).  
In 2016, a study (50) confirmed the existence of a feedback loop: ILK-Akt-NF-kB-IL-6.  
This signal loop was shown to activate E2F1 expression through STAT3/cyclin 
D1/CDK2 signaling. Since E2F1 is a well-known cell cycle regulator and CDK8 is one of 
the important kinases which negatively regulates E2F1.  It also has been shown (51) that 
there is a direct link between E2F1 and apoptotic machinery, especially the expression 
level of the pro-apoptotic BH3-only proteins PUMA, NOXA, BIM and Hrk/DP5.  
The above experimental evidence and literature presented suggest that Q-12 
inhibits STAT1 phosphorylation and promotes STAT3 phosphorylation, which results in 
modulating the expression of key anti- and pro-apoptotic proteins Mcl-1 and PUMA.  
The change in balance between Mcl-1 and PUMA likely results in the promotion of 
apoptosis in MDA-MB-468 cells.  The specific mechanism is likely due to CDK8 
inhibition, which is known to phosphorylate STAT1, and may additionally involve E2F1.   
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Conclusions 
 
In MDA-MB-468 and COLO-205 cell lines, Q-12 modulated transcriptional 
factor p-STAT1 reduction.  In colorectal cancer cell line, COLO-205, Q-12 induced β-
catenin reduction, but not in triple negative breast cancer cell line, the MDA-MB-468.  
The expression of p-STAT3 (Ser727) was modulated by Q-12 in MDA-MB-468 cell line 
only.  Further, inhibiting p-STAT3 increase due to Q-12 treatment by CPT was shown to 
rescue the MDA-MB-468 cell viability.  CPT inhibited the modulation of apoptosis 
proteins, Mcl-1 and PUMA, due to Q-12 treatment.  Q-12 activity in MDA-MB-468 cell 
line is dependent on the activation of STAT3 phosphorylation.  
Studies (33) have shown that CDK8 is an important modulator of both β-catenin 
and E2F1, whereas CDK8 enhances the activity of β-catenin, it represses the activity of 
E2F1 in colorectal cancers.  Consequently, the amplification of CDK8 may act as a 
switch, allowing increased β-catenin-dependent transcription that is also resistant to E2F1 
inhibition.  So, the inhibition of CDK8 combined with the activation of E2F1, may be 
useful as a two-pronged strategy to target cancer cells that are driven by deregulated β-
catenin activity (10).  
Our results indicated that STAT3 activation and apoptotic proteins: PUMA and 
Mcl-1 play an important role in Q-12 regulation in MDA-MB-468 cell line.  Whether 
E2F1 is the key regulator in the apoptosis process induced by Q-12 and how Q-12 
modulates E2F1 expression still needs to be further investigated.  One way to probe E2F1
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engagement upon Q-12 treatment in MDA-MB-468 cell line is to use small interfering 
RNA to prevent the re-activation of E2F1.  SiRNA of E2F1 will interfere with the 
expression of E2F1 genes with complementary nucleotide sequences by degrading its 
mRNA after transcription.  If knocking down E2F1 protects the cell from Q-12, which 
will suggest that E2F1 activation would be critical for the apoptosis process in the MDA-
MB-468 cells upon Q-12 treatment and confirm p-STAT3 involvement through the IL-6 
feedback loop (50).   
To study the mechanisms of anti-proliferative effect of Q-12 is an important and 
necessary step to further identify potential biomarkers for human cancer sensitivity to 
CDK8 inhibitors.  Biomarkers could help predict a priori whether an individual patient 
will respond to the treatment of choice as well as provide an early distinction of 
responders and non- responders during therapy.  In the future, clinical predictions based 
on molecular biomarkers will greatly improve clinical care and patient outcomes.
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